|
Today's Headlines
FDA warned September 27 of an increased risk of death associated with intravenous tigecycline (Tygacil) for FDA-approved and non-approved uses.
» Full article
|
|
Digoxin, commonly used to treat heart conditions, was associated with a 72% higher rate of death among adults with newly diagnosed heart failure, according to a Kaiser Permanente study in the September issue of Circulation: Cardiovascular Quality and Outcomes. » Full article
|
|
Under priority review, FDA approved pertuzumab (Perjeta, Genentech, a member of the Roche Group) on September 30 as part of a complete treatment regimen for patients with early-stage breast cancer before surgery. » Full article
|
|
In adult patients with type 2 diabetes mellitus who are uncontrolled on metformin and sulfonylurea, dapagliflozin can be added to help improve HbA1c and reduce fasting plasma glucose, body weight, and seated systolic blood pressure, according to results from a study presented at the 49th Annual Meeting of the European Association for the Study of Diabetes in Barcelona, Spain, in September. » Full article
|
Continuing Education
This month, Drug Topics offers the first part of a two-part CPE series, "MTM considerations in osteoporosis care." Earn up to 2 credits by completing this application-based activity.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
|
Like
Tweet
